Company Overview
About Kilobaser
Kilobaser is a Vienna, Austria-based biotechnology hardware company — backed by Y Combinator (W21) with $1.99 million in total funding from BioTools Innovator — providing research laboratories and life sciences companies with desktop DNA and RNA oligonucleotide synthesizers that enable individual scientists to produce custom synthetic DNA sequences directly on their benchtops without sending samples to commercial synthesis services, generating $3.1 million in annual revenue in 2024 with consistent revenue growth since the 2014 company founding. Positioned as the "Nespresso Machine for DNA," Kilobaser offers the Basic Edition synthesizer ($35,500) and Extended Edition ($49,500) — compact, affordable instruments that democratize access to on-demand DNA synthesis for research labs that need rapid turnaround on custom oligonucleotide sequences for PCR primers, CRISPR guides, sequencing adapters, and synthetic gene construction.
Business Model & Competitive Advantage
Kilobaser's desktop DNA synthesis model addresses the supply chain bottleneck created by commercial oligonucleotide synthesis services: research labs currently order custom DNA sequences from commercial providers (Integrated DNA Technologies, Twist Bioscience, Genewiz) and wait 24-72 hours for overnight shipping of the synthesized oligos — a turnaround time that creates calendar friction in experiments requiring iterative sequence optimization (CRISPR guide RNA screening, primer optimization, aptamer selection) where the researcher wants results in the same day. Kilobaser's benchtop synthesizer (automated solid-phase phosphoramidite chemistry in a compact instrument format) enables on-demand synthesis of custom 8-30mer DNA sequences within 3-4 hours in the researcher's own lab — supporting the rapid design-synthesize-test cycles that accelerate research. The cartridge-based reagent system (comparable to Nespresso's pod approach) simplifies the chemistry consumable management that makes traditional DNA synthesis instruments impractical for non-specialist labs.
Competitive Landscape 2025–2026
In 2025, Kilobaser competes in the benchtop DNA synthesis instruments, oligonucleotide manufacturing, and life sciences research equipment market with Twist Bioscience (NASDAQ: TWST, synthetic DNA and oligo pools), Integrated DNA Technologies (Danaher subsidiary, NYSE: DHR, large-scale commercial oligo synthesis), and Evonetix (benchtop DNA synthesis instrument, $30M raised) for research lab on-demand DNA synthesis adoption. The democratization of DNA synthesis (making gene construction tools available to individual researchers rather than only centralized synthesis facilities) is a recurring theme in life sciences tool innovation — Kilobaser's benchtop instrument follows the pattern of PCR (made accessible by low-cost thermal cyclers), DNA sequencing (made accessible by benchtop sequencers like Oxford Nanopore's MinION), and cell counting. Y Combinator W21 backing positioned Kilobaser in the biotech tools investor community. The 2025 strategy focuses on growing the academic lab market (individual PI labs at universities), building the RNA synthesis capability extension (for siRNA and mRNA research), and expanding the reagent cartridge subscription revenue model.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Kilobaser is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Kilobaser with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Kilobaser? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Kilobaser Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Kilobaser vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →